MDT
Not exactly a bad Wednesday for MDT
Medtronic came out swinging with fourth-quarter revenue of $9.81 billion, topping Wall Street’s $9.64 billion estimate, while adjusted EPS landed at $1.55 versus $1.54 expected. In other words: not a blowout, but enough to make the Street shrug and say, “Fine, you’ve got my attention.”
BTIG says the discount looks too chunky
BTIG upgraded Medtronic from Neutral to Buy and slapped a $90 price target on it. Analyst Ryan Zimmerman’s basic thesis: Medtronic is growing steadily, the durability is real, and the stock still trades like the market hasn’t fully woken up to that combo meal of income + consistency.
The firm highlighted a few things that matter:
- organic growth is running at a healthier clip
- stronger momentum is showing up across more segments
- M&A and new products could keep the story moving
Why investors should care
This isn’t just “yay, earnings beat.” It’s the kind of report that can reframe a boring giant into a more interesting one. Medtronic’s Cardiovascular and Diabetes businesses helped power the quarter, which gives the bull case a little more juice than a one-segment miracle story.
The stock was already up 4.3% to $81.30 around the report, so the market clearly liked the setup. Big picture: when a healthcare heavyweight starts looking more like a growth-and-income machine than a sleepy defensive name, people start redoing their spreadsheets.